Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the statin class of cholesterol-lowering drugs. Lovastatin is an HMG-CoA reductase inhibitor that was initially isolated from Aspergillus terreus. Marketed as Mevinolin™, Mevacor™, and under several other trade names, Lovastatin was the first HMG-CoA reductase inhibitor to be used in the treatment of hypercholesterolemia. It is a competitive inhibitor of HMG-CoA reductase with a Ki value of 0.6 nM for the open ring, hydroxy acid form of the molecule. During a three week study in dogs, a dose of 8 mg/kg per day resulted in a 29% reduction in plasma cholesterol. Lovastatin also suppresses TNF-induced NF- kappa B activation (IC50 ~ 15 µM), which potentiates apoptosis in human myeloid leukemia cells and thus, maybe useful in treating cancer.
Lovastatin is supplied as a crystalline solid. A stock solution may be made by dissolving the lovastatin in an organic solvent purged with an inert gas. Lovastatin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of lovastatin in ethanol and DMSO is approximately 20 mg/ml and approximately 15 mg/ml in DMF. Lovastatin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lovastatin should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Lovastatin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Tobert, J.A. Nature Reviews Drug Discovery 2, 517-526 (2003).
Endo, A. J. Lipid Res. 33, 1569-1582 (1992).
Alberts, A.W., Chen, J., Kuron, G., et al. Proc. Natl. Acad. Sci. USA 77(7), 3957-3961 (1980).